Achilles Therapeutics plc ACHL
At closeMar 20, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- +29.82%
- 1 year
- +14.73%
- Market cap
- 60.83M
- Shares out
- 41.09M
- Forward P/E
- -0.61
- YTD return
- +29.82%
- 1-year return
- +14.73%
- Volume
- 1.20M
- Open
- 1.48
- Previous close
- 1.48
- Day's range
- 1.48 – 1.48
- Beta
- 1.34
- Analysts
- Buy
- Earnings date
- Aug 14, 2024
1Y +0.25 (+20.33%)
Key statistics
- Enterprise value
- -46.68M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -30.14M
- Total cash
- 95.11M
- Total debt
- 4.46M
- Return on equity
- -44.22%
- Short % of float
- 0.63%
- 50-day average
- 1.02
- 200-day average
- 0.91881
Analyst view
Consensus: buy
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.41 | -0.48 | -0.07 | -17.07% |
| Aug 14, 2024 | Jun 1, 2024 | -0.41 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.41 | -0.41 | 0.00 | 0.00% |
| May 8, 2024 | Mar 1, 2024 | -0.46 | -0.30 | +0.16 | +34.78% |
| May 8, 2024 | Mar 1, 2024 | -0.46 | — | — | — |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 5, 2024 | Chardan Capital | main | Buy | Buy |
| Apr 5, 2024 | Piper Sandler | down | Overweight | Neutral |
| Dec 14, 2023 | B of A Securities | down | Buy | Underperform |
| Aug 7, 2023 | Chardan Capital | reit | Buy | Buy |
| May 11, 2023 | Chardan Capital | main | Buy | Buy |
| Dec 7, 2022 | Chardan Capital | main | — | Buy |
About Achilles Therapeutics plc
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- achillestx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ACHL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Syncona Portfolio Ltd | 26.98% | 11,086,909 | 12.64M | Sep 29, 2024 |
| BML Capital Management, LLC | 9.98% | 4,100,002 | 4.67M | Sep 29, 2024 |
| Fcpm III Services B.v. | 5.82% | 2,390,050 | 2.72M | Sep 29, 2024 |
| Redmile Group, LLC | 3.91% | 1,608,089 | 1.83M | Sep 29, 2024 |
| Vestal Point Capital, LP | 3.65% | 1,500,000 | 1.71M | Sep 29, 2024 |
| Ikarian Capital, LLC | 3.51% | 1,443,181 | 1.65M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 21,590 | 24.61K | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 100 | 113 | Sep 29, 2024 |